Catalyst Pharmaceuticals (CPRX) Cash from Financing Activities (2011 - 2026)

Catalyst Pharmaceuticals has reported Cash from Financing Activities for 16 years, with the latest figure at -$12.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 520.65% year-over-year to -$12.9 million; the trailing twelve-month figure through Mar 2026 stood at -$32.9 million (down 1330.42% YoY), and the FY2025 full-year result was -$17.0 million, down 112.08% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$12.9 million, up from -$25.6 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $141.0 million in Q1 2024, with the low at -$25.6 million in Q4 2025.
• Historically, Cash from Financing Activities has averaged $6.0 million across 5 years, with a median of $149000.0 in 2023.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 925.0% — and 2024, when it surged 94563.76%.
• Catalyst Pharmaceuticals' Cash from Financing Activities stood at $2.3 million in 2022, then sank by 129.52% to -$665000.0 in 2023, then jumped by 766.62% to $4.4 million in 2024, then sank by 677.04% to -$25.6 million in 2025, then jumped by 49.68% to -$12.9 million in 2026.
• The last three Cash from Financing Activities figures came in at -$12.9 million (Q1 2026), -$25.6 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.